HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on Silence Therapeutics (NASDAQ:SLN) and maintained a $75 price target on the company's stock.
January 18, 2024 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms Buy rating and $75 price target for Silence Therapeutics (NASDAQ:SLN), indicating a positive outlook for the stock.
The reiteration of a Buy rating and the maintenance of a high price target by a reputable analyst can lead to increased investor confidence and potential upward movement in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100